Walgreens booked a better-than-expected fiscal first quarter and gave Wall Street some positive vibes on the drugstore chain’s plan to revive its struggling business.

Walgreens improving pharmacy business and comments from the company’s CEO are convincing Wall Street that the drugstore won't succumb to a private equity buyout.

Walgreens Boots Alliance Inc. reported quarterly results that surpassed Wall Street’s expectations, easing pressure on the pharmacy chain as it mulls strategic options including a sale.

The troubled retail pharmacy chain Walgreens Boots Alliance reported financial results early Friday that weren’t quite as bad as analysts had anticipated, sending shares sharply higher in morning trading.

Walgreens Tops Wall Street's Expectations as Drugstore Chain Continues Turnaround Plan Walgreens booked a better-than-expected fiscal first quarter and gave Wall Street some positive vibes on the ...

Walgreens booked a better-than-expected fiscal first quarter, but the drugstore chain lost $265 million as it closed U.S. stores and continued work to revive its business Walgreens booked a better ...

Walgreens booked a better-than-expected fiscal first quarter and gave Wall Street some positive vibes on the drugstore chain's plan to revive its struggling business. Company shares soared Friday ...

Walgreens booked a better-than-expected fiscal first quarter and gave Wall Street some positive vibes on the drugstore chain’s plan to revive its struggling business. Company shares soared ...

However, ten companies under mixed sectors bucked an overall positive market sentiment as multiple negative factors put pressure on investor sentiment.

The pharmacy chain since August 2012 filled prescriptions that lacked a legitimate medical purpose, were invalid or weren’t issued in professional practice, the Justice Department said.

The pharmacy “allowed millions of opioid pills and other controlled substances to flow illegally out of Walgreens stores,” the Justice Department said.

Shares of Walgreens Boots Alliance fell after the Justice Department sued the company for allegedly helping to fuel the opioid crisis. The company's stock fell 9% to $11.39 after the market closed Friday. It is down 43% over the past 12 months.